Monthly Archives: October 2012

Pfizer Catches NextWave

Pfizer has acquired NextWave Pharmaceuticals, whose main asset is the recently approved Quillivant for ADHD, which is a liquid formulation of CR methylphenidate. Pfizer had optioned the company for $20 million a few months ago, another $255 million is payable … Continue reading

Posted in Uncategorized | Tagged , , , , , | Leave a comment

Chinese Data Torture

Drip…drip…drip. The solanezumab results continue to trickle out. In August, Lilly announced that the two Phase III trials had missed their endpoints, but data from mild Alzheimer’s patients pointed to a possible treatment effect on cognition, but not on functioning. … Continue reading

Posted in Uncategorized | Tagged , , | Leave a comment